Growth Metrics

Incyte (INCY) Shares Outstanding (Weighted Average) (2010 - 2026)

Incyte posted quarterly Shares Outstanding (Weighted Average) of $199.3 million for Q1 2026, up 2.91% year-on-year from $193.7 million in Q1 2025, and up 2.12% on a QoQ basis from $195.2 million in Q4 2025.

Incyte (INCY) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $199.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 2.91% year-over-year to $199.3 million; the trailing twelve-month figure through Mar 2026 stood at $199.3 million (up 2.91% YoY), and the FY2025 full-year result was $195.2 million, down 5.75% from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 stood at $199.3 million, up from $195.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $224.5 million in Q1 2024 and bottomed at $193.7 million in Q1 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $221.3 million (2022), against an average of $212.9 million.
  • The widest annual swing landed in 2025, when Shares Outstanding (Weighted Average) decreased 13.71%; it then climbed 2.91% in 2026.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $222.0 million in 2022, then rose by 0.73% to $223.6 million in 2023, then declined by 7.39% to $207.1 million in 2024, then slipped by 5.75% to $195.2 million in 2025, then increased by 2.12% to $199.3 million in 2026.
  • The last three Shares Outstanding (Weighted Average) figures came in at $199.3 million (Q1 2026), $195.2 million (Q4 2025), and $195.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 177,333.76 Bn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - 185,491.37 Bn
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 100.00 Bn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - 55.66 Bn
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 118.76 Bn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 254.10 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - 16.04 Bn
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 104.00 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 132.89 Mn
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn 199.34 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 199.34 Mn
Dec 31, 2025 195.20 Mn
Sep 30, 2025 195.67 Mn
Jun 30, 2025 194.00 Mn
Mar 31, 2025 193.71 Mn
Dec 31, 2024 207.11 Mn
Sep 30, 2024 211.76 Mn
Jun 30, 2024 218.18 Mn
Mar 31, 2024 224.48 Mn
Dec 31, 2023 223.63 Mn
Sep 30, 2023 223.43 Mn
Jun 30, 2023 223.10 Mn
Mar 31, 2023 222.96 Mn
Dec 31, 2022 222.00 Mn
Sep 30, 2022 222.42 Mn
Jun 30, 2022 221.49 Mn
Mar 31, 2022 221.33 Mn
Dec 31, 2021 220.43 Mn
Sep 30, 2021 220.24 Mn
Jun 30, 2021 219.94 Mn
Mar 31, 2021 219.80 Mn
Dec 31, 2020 218.07 Mn
Sep 30, 2020 217.68 Mn
Jun 30, 2020 217.55 Mn
Mar 31, 2020 216.72 Mn
Dec 31, 2019 214.91 Mn
Sep 30, 2019 215.20 Mn
Jun 30, 2019 214.62 Mn
Mar 31, 2019 214.07 Mn
Dec 31, 2018 212.38 Mn
Sep 30, 2018 212.63 Mn
Jun 30, 2018 212.21 Mn
Mar 31, 2018 211.68 Mn
Dec 31, 2017 204.58 Mn
Sep 30, 2017 206.80 Mn
Jun 30, 2017 205.14 Mn
Mar 31, 2017 195.26 Mn
Dec 31, 2016 187.87 Mn
Sep 30, 2016 188.03 Mn
Jun 30, 2016 187.68 Mn
Mar 31, 2016 187.18 Mn
Dec 31, 2015 179.60 Mn
Sep 30, 2015 181.39 Mn
Jun 30, 2015 178.68 Mn
Mar 31, 2015 172.07 Mn
Dec 31, 2014 167.95 Mn
Sep 30, 2014 168.59 Mn
Jun 30, 2014 167.91 Mn
Mar 31, 2014 165.36 Mn
Dec 31, 2013 148.40 Mn
Sep 30, 2013 155.07 Mn
Jun 30, 2013 142.28 Mn
Mar 31, 2013 134.35 Mn
Dec 31, 2012 129.75 Mn
Sep 30, 2012 130.85 Mn
Jun 30, 2012 129.22 Mn
Mar 31, 2012 127.20 Mn
Dec 31, 2011 125.36 Mn
Sep 30, 2011 126.26 Mn
Jun 30, 2011 125.33 Mn
Mar 31, 2011 123.47 Mn
Dec 31, 2010 121.63 Mn
Sep 30, 2010 122.19 Mn
Jun 30, 2010 121.63 Mn
Mar 31, 2010 119.73 Mn